drugset

drugset / Trial / NCT05127759

The Efficacy and Safety of HLX208 in Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation

NCT05127759 ↗

Phase 2 Unknown 25 enrolled Shanghai Henlius Biotech

NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to assess efficacy, safety and PK in metastatic colorectal cancer (mCRC) given HLX208 (BRAF V600E inhibitor).

Timeline

Start: 2022-03-23
Primary completion: 2024-01-30
Completion: 2025-06-28

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	HLX208	Unknown	450 mg	Oral

Indications